Dean Capital Investments Management LLC bought a new position in shares of Genmab A/S (NASDAQ:GMAB) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 33,003 shares of the company’s stock, valued at approximately $669,000.
Several other institutional investors have also recently added to or reduced their stakes in GMAB. Parametric Portfolio Associates LLC acquired a new stake in shares of Genmab A/S during the second quarter worth about $6,937,000. Private Capital Group LLC acquired a new stake in shares of Genmab A/S during the second quarter worth about $41,000. Signaturefd LLC acquired a new position in Genmab A/S in the third quarter valued at approximately $48,000. Envestnet Asset Management Inc. acquired a new position in Genmab A/S in the third quarter valued at approximately $2,698,000. Finally, Brinker Capital Inc. acquired a new position in Genmab A/S in the third quarter valued at approximately $988,000. 1.37% of the stock is owned by hedge funds and other institutional investors.
Shares of Genmab A/S stock traded up $0.04 on Tuesday, reaching $22.12. The company’s stock had a trading volume of 1,265 shares, compared to its average volume of 199,919. Genmab A/S has a 52-week low of $13.64 and a 52-week high of $22.20. The business has a 50-day simple moving average of $20.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 18.72 and a quick ratio of 18.72.
A number of research analysts have issued reports on the company. Bank of America raised Genmab A/S from a “neutral” rating to a “buy” rating in a report on Friday, September 13th. HC Wainwright boosted their price target on Genmab A/S from $24.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Royal Bank of Canada assumed coverage on Genmab A/S in a report on Monday, August 12th. They issued an “outperform” rating and a $23.00 price target for the company. JPMorgan Chase & Co. raised Genmab A/S from a “neutral” rating to an “overweight” rating and set a $23.00 price target for the company in a report on Thursday, September 12th. Finally, Morgan Stanley assumed coverage on Genmab A/S in a report on Monday, August 12th. They issued an “overweight” rating for the company. Six analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $23.67.
Genmab A/S Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Featured Article: Monthly Dividend Stocks
Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMAB).
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.